BCC Research Launches Strattera® Forecast; Strategic Investment Tool Provides Market Intelligence for Strattera® -Related Opportunities

BCC Research (http://www.bccresearch.com) is pleased to announce the BCC Research Strattera® Forecast, a strategic investment product designed to provide market data for the pharmaceutical drug, Strattera®, a treatment for Attention Deficit Hyperactivity Disorder (ADHD) distributed by Eli Lilly and Company. Strattera® will lose its branded patent protection in late 2016 going into 2017, opening the market to distribution of generic treatments by competing companies.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
BCC Research Launches Strattera® Forecast; Strategic Investment Tool Provides Market Intelligence for Strattera-Related Opportunities

Wellesley, Mass., (PRWEB) July 02, 2014

BCC Research (http://www.bccresearch.com) is pleased to announce the BCC Research Strattera® Forecast, a strategic investment product designed to provide market data for the pharmaceutical drug, Strattera®, a treatment for Attention Deficit Hyperactivity Disorder (ADHD) distributed by Eli Lilly and Company. Strattera® will lose its branded patent protection in late 2016 going into 2017, opening the market to distribution of generic treatments by competing companies.

Through its Strattera® Forecast, BCC Research provides high-quality intelligence for strategic decision-making regarding future participation in the ADHD treatment market. The product can be used to examine forecasted market demand for Strattera®, to identify new business and investment opportunities for related products and services, and to validate other Strattera® market-demand data.

Strattera® Forecast is a quantitative model in an easily accessible Microsoft® Excel® spreadsheet, featuring market demand forecasts for Strattera® annually for the years 2010 to 2030 by volume and value (USD). The interactive forecast incorporates populations for the regions included, ADHD diagnosis and prevalence rates, and product pricing forecasts. It segments the market for the following regions: United States, Japan, France, Germany, Italy, Spain, and the UK.

Strattera® is a selective norepinephrine reuptake inhibitor (NRI) from Eli Lilly and Company approved for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children aged 6 and older, teens, and adults. It is generally used as part of a total treatment program for ADHD that may include counseling or other therapies.

About BCC Research

BCC Research publishes market research reports that make organizations worldwide more profitable with intelligence that drives smart business decisions. These reports cover today's major industrial and technology sectors, including emerging markets. For more than 40 years, we have helped customers identify new market opportunities with accurate and reliable data and insight, including market sizing, forecasting, industry overviews, and identification of significant trends and key competitors. We partner with analysts who are experts in specific areas of industry and technology, providing unbiased measurements and assessments of global markets. Our clients include the top companies in industries around the world as well as universities, business schools, start-ups, consulting firms and investment companies. BCC Research is a unit of Eli Research LLC. Visit our website at http://www.bccresearch.com. Contact us: (+1) 781-489-7301 (U.S. Eastern Time), or email information(at)bccresearch(dot)com.

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC, 49-2 Walnut Park, Wellesley, MA 02481, Telephone: (+1) 781-489-7301; Email: editor(at)bccresearch(dot)com as the source and publisher. Thank you.


Contact